New Lung Cancer Treatments Show Real Promise
New 2025 Research Brings Hope for Advanced Lung Cancer
New research shared in 2025 brings hope for people with advanced non-small cell lung cancer. Scientists presented several treatment updates that are helping patients live longer with fewer side effects. One medicine, aumolertinib, helped slow cancer growth—especially when combined with chemotherapy. Aumolertinib is a targeted therapy that blocks the EGFR protein, which drives tumor growth in certain lung cancers. When added to chemotherapy, it has been shown to significantly delay cancer progression and is generally well tolerated. Another drug, JYP0322, worked well for people with a rare type of lung cancer, even when the cancer had spread to the brain. JYP0322 is an investigational ROS1 inhibitor designed to cross the blood-brain barrier, making it effective against brain metastases. Early trials showed promising responses in patients who had previously received other ROS1-targeted treatments.
Other promising treatments are helping people whose cancer carries uncommon genetic changes. A pill called zongertinib helped many patients and caused fewer side effects than older drugs. Zongertinib targets HER2-mutated lung cancer, which is rare but often aggressive. Clinical studies showed it shrinks tumors effectively and causes fewer side effects compared with older treatments. Another new medicine, zoldonrasib, showed early success in shrinking tumors in patients whose cancer had stopped responding to other treatments. While one immune-based drug didn’t work as well as hoped, researchers believe it still has potential. Zoldonrasib, is designed for cancers with the KRAS G12D mutation, a mutation that was historically difficult to treat. Early trial results indicate it can shrink tumors in patients whose cancer no longer responds to standard therapies. Overall, the message is clear: more personalized and effective treatments are on the horizon. (Source: American Association for Cancer Research)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like advanced lunch cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Gene Therapy Gives Stage 4 Mom More Time
Sara Whitlock: Thriving After Stage 4 Lung Cancer Diagnosis
Sara Whitlock was diagnosed with stage 4 lung cancer in 2010 at just 47. She feared she wouldn’t live to see her daughters grow up. Her outlook was bleak—only a 3% chance of surviving five years. Yet more than a decade later, Sara is thriving, watching her daughters graduate and enjoying everyday life with her husband. Her journey began with traditional chemotherapy and radiation. A major turning point came in 2017 when she joined a clinical trial for a gene-targeted therapy called selpercatinib (LOXO-292). The drug is designed for patients with a rare mutation called RET fusion-positive non-small cell lung cancer, found in only about 2% of lung cancer patients.
Sara’s story is a powerful example of how targeted therapies, drugs developed to block specific cancer-driving mutations, are transforming treatment and survival for people with advanced lung cancer. Unlike the harsh side effects of earlier treatments, this pill-based therapy has been easier to tolerate, and Sara currently has no signs of cancer. While she remains aware that her cancer could return, she’s living fully and cherishing every moment. Her story is a reminder that even with a stage 4 diagnosis, new research and personalized treatments are rewriting the possibilities for patients—and their families. (Source: Cleveland Clinic)
Read the complete article here. >
Resources for Living With Stage 4 Cancer
Learn more about topics like stage 4 cancer stories by becoming a member of our community. Gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
26 Years Living With Stage 4 Lung Cancer
Wells Stage 4 Lung Cancer Survivor Story
When Wells W. was diagnosed with stage 4 lung cancer in 1998, doctors told him he had just 10 months to live. But Wells, a scientist by training, took charge of his care—researching treatments, getting second opinions, and joining a compassionate use trial for Iressa (gefitinib), a targeted therapy that matched his EGFR mutation. His tumors shrank enough for surgery, and he’s continued to live cancer-managed ever since.
Now 91, Wells has dedicated his life to lung cancer advocacy, co-founding GO2 for Lung Cancer and mentoring others facing the disease. His journey proves that even with a stage 4 diagnosis, hope, action, and long-term survival are possible. (Source: GO2 for Lung Cancer)
Caroline’s Story: Facing Lung Cancer with Family and Hope
Caroline’s EGFR Lung Cancer Genetic Mutation Story
Caroline, a nurse practitioner from Louisiana, knows the impact of lung cancer firsthand due to her family’s experience. Several relatives who never smoked developed lung cancer, prompting genetic testing that revealed an EGFR gene mutation affecting Caroline, her mother, and grandmother. Shortly after having her baby, Caroline’s own lung screening showed nodules, leading to surgery and challenging complications that required multiple hospitalizations. She eventually found a supportive medical team closer to home at MD Anderson, where she continues to receive regular screenings.
Embracing a positive outlook, Caroline draws strength from her family and friends and actively raises awareness about genetic mutations in lung cancer, inspired by her meeting with Dr. Geoff Oxnard, hoping her experience will encourage and inform others. (Source: EGFR Resisters)
Targeted Pill Delays Lung Cancer Return
Tagrisso (Osimertinib) Delays EGFR Lung Cancer Recurrence
A new treatment is bringing hope to people with stage 3 non-small cell lung cancer (NSCLC) that has a mutation in a gene called EGFR, which stands for epidermal growth factor receptor. This gene helps cells grow, and when it’s mutated, it can cause cancer to grow faster. These EGFR mutations are found in many people with lung cancer—especially never smokers and those of Asian descent.
In the LAURA trial, patients who had already completed chemotherapy and radiation were given the pill Tagrisso (osimertinib) to help prevent their cancer from coming back. The study, led by Dr. Suresh Ramalingam of Winship Cancer Institute at Emory University, showed powerful results: people who took Tagrisso stayed cancer-free for a median of 39 months—compared to just 5.6 months in the group that didn’t take the drug. That means Tagrisso reduced the risk of cancer returning or spreading by 84%.
Tagrisso (osimertinib) is a once-daily targeted therapy used to treat EGFR-mutated non-small cell lung cancer. It works by blocking the abnormal EGFR signals that cause cancer cells to grow, helping delay recurrence and slow disease progression. Tagrisso has become a standard treatment in several stages of EGFR-positive lung cancer and is especially valued for its ability to help protect against cancer spreading to the brain.
While some patients experienced side effects like inflammation in the lungs, no new safety issues were found. Tagrisso is now the first targeted therapy to show such a strong benefit for stage 3 EGFR-positive lung cancer. Doctors believe this could become the new standard of care—offering more time and hope to patients with this aggressive form of lung cancer. (Source: Winship Cancer Institute at Emory University)
Three New Lung Cancer Treatments Show Promise
Three New Lung Cancer Treatments in 2025 Showing Promise at ASCO
At the 2025 ASCO cancer meeting, researchers shared encouraging updates on new treatments for both small cell and non-small cell lung cancer. One study showed that tarlatamab, a new type of targeted immunotherapy, helped patients with recurrent small cell lung cancer live longer with fewer side effects than standard chemotherapy — even in cases where the cancer had spread to the brain. This is an especially hopeful sign for a disease with very few second-line treatment options.
Another study focused on a pill called zipalertinib, developed for patients with an uncommon EGFR mutation (exon 20 insertion). Many of these patients had already tried chemotherapy or other targeted treatments with limited success. In the trial, zipalertinib shrank tumors in about one-third of patients, including those whose cancer had progressed or reached the brain. A third trial found that giving the targeted drug osimertinib before surgery helped shrink tumors in EGFR-positive lung cancer, and may reduce the chances of the cancer coming back.
These advances show how targeted therapies are becoming more personalized and effective — even for hard-to-treat lung cancers. For many patients, they represent not just longer life, but better quality of life. (Source: Memorial Sloan Kettering)
Vitamin C Boosts Cancer Survival
IV Vitamin C Shows Promise in Advanced Cancer Clinical Trial
A new study offers hope for patients facing some of the toughest cancer diagnoses. In a phase 2 clinical trial, adding high-dose intravenous (IV) vitamin C to standard chemotherapy nearly doubled survival for people with advanced pancreatic cancer—from 8 months to 16 months. Patients also reported feeling better during treatment, with fewer side effects and improved ability to tolerate therapy. This research adds to a growing body of evidence suggesting that high-dose IV vitamin C could help improve both survival and quality of life for people with aggressive cancers.
Researchers at the University of Iowa have spent nearly 20 years studying the effects of vitamin C delivered by IV rather than by mouth, where it can reach levels high enough to damage cancer cells while leaving healthy cells mostly unharmed. Encouraging results have also been seen in brain cancer and are being studied in lung cancer. Experts say that because vitamin C is low-cost and well tolerated, it could become a helpful add-on to treatment—not just for pancreatic cancer, but for other difficult-to-treat cancers as well. (Source: University of Iowa Health Care / Redox Biology)
Breaking the Stigma Around Lung Cancer
Breaking Misconceptions and Supporting Patient
Many people with lung cancer face stigma and blame, even from loved ones and healthcare providers. Learn why lung cancer is no one’s fault.
More than half of people with lung cancer report feeling judged or blamed by friends, family, and even healthcare providers. Because lung cancer has long been linked to smoking, many assume it’s the patient’s fault. But the reality is different: anyone with lungs can develop lung cancer, including those who have never smoked or who quit years ago.
Stigma doesn’t just hurt feelings—it can actually keep people from getting screened or treated promptly, harming their health. Experts emphasize that lung cancer is no one’s fault; nicotine addiction is difficult to overcome, and no patient deserves blame. Recognizing and reducing lung cancer stigma helps ensure all patients receive the compassion and medical support they deserve. (Source: Memorial Sloan Kettering)
9 Common Questions About Genetic Testing for Cancer
How Knowing Your Risk Can Guide Treatment
For patients facing stage 4 lung cancer or those with a strong family history of cancer, genetic testing can offer clarity, guidance, and hope. About 10% of cancers are hereditary, meaning they are driven by inherited gene mutations that can be passed through families. Testing for these mutations, such as BRCA1, BRCA2, and others linked to lung or related cancers, helps doctors understand a patient’s personal cancer risk and may also guide treatment choices—especially for targeted therapies.
Importantly, having a gene mutation doesn’t mean you’ll definitely get cancer, but it does raise your risk. If you already have cancer, genetic testing can sometimes influence treatment decisions, like choosing one type of chemotherapy or surgery over another. For those with a family history, testing can alert relatives to start earlier cancer screenings or preventive measures. Bringing a detailed family history to your genetic counseling appointment can be a valuable first step.
Knowing your genetic risk empowers you to take proactive steps—whether that’s enrolling in clinical trials, pursuing early screening, or helping your children understand their potential risks. While we can’t change our genes, we can change how we respond to what they tell us. (Source: Mayo Clinic)
Stage4Hope Launches to Transform Advanced-Stage Cancer Care
Stage4Hope Launches to Support Patients with Cancer
Stage4Hope™, a new 501(c)(3) nonprofit founded by stage IV lung cancer patient Stacy L. Carter, launches to accelerate access to expert cancer care, provide emotional and financial support, and advance precision oncology research.
We are pleased to announce the official launch of Stage4HopeTM, a 501(c)(3) public charity! We have a powerful mission: to improve the lives of individuals diagnosed with advanced-stage cancer by accelerating access to world-class cancer care, providing financial and emotional support, and investing in cutting-edge research in precision oncology.
Founded by Stacy L. Carter—a mother, entrepreneur, and non-smoker diagnosed with stage IV lung cancer in 2023—Stage4Hope was born out of her own journey and the urgent need to bring hope, clarity, and purpose to others facing similar diagnoses.
“I started Stage4Hope because I know what it’s like to hear the words ‘stage IV’ and to have my whole world fall apart,” says Stacy. “What carried me forward was finding purpose in the midst of the pain. Now, we’re building a place where patients can access expert care quickly, find emotional healing, and rediscover hope and purpose—even in the middle of the storm.”
Top Questions to Ask After a Lung Cancer Diagnosis
If you or a loved one has been diagnosed with lung cancer, knowing what questions to ask can make a major difference in your treatment journey. Dr. Mark Awad, a leading lung cancer expert at Memorial Sloan Kettering (MSK), emphasizes the importance of understanding your specific type and stage of lung cancer — whether it’s small cell or non-small cell — and making sure all the necessary scans have been done to determine where the cancer is in the body. It’s also vital to ask about comprehensive genomic and biomarker testing, which can uncover genetic mutations and guide your doctors to the most effective, personalized treatment options, including immunotherapy or targeted drugs.
Dr. Awad also stresses the value of being treated by a dedicated lung cancer team with extensive experience, and encourages patients to seek a second opinion to ensure the best care. While starting treatment quickly may feel urgent, gathering complete information first often leads to better long-term outcomes. Many treatment centers, including MSK, offer care options closer to home and provide support services to help manage side effects, improve quality of life, and support emotional and practical needs. Most importantly, communicate openly with your care team about your goals and what’s most meaningful to you — so your treatment can support your whole life, not just your diagnosis. (Source: Memorial Sloan Kettering Cancer Center)
Hope for KRAS-G12D Lung Cancer
KRAS-G12D Lung Cancer Clinical Trial Shows Promising Results
Memorial Sloan Kettering Cancer Center researchers have reported promising results from a first-of-its-kind clinical trial targeting the KRAS-G12D mutation in non-small cell lung cancer (NSCLC). The experimental drug zoldonrasib (RMC-9805) demonstrated significant tumor shrinkage in 61% of participants who had previously not responded to standard treatments. These findings offer hope for patients with this challenging mutation subtype.
- « Previous
- 1
- 2
- 3
